《Citeline&ASGCT：2025年第一季度基因、细胞和 RNA 疗法概况报告（英文版）（55页）.pdf》由会员分享，可在线阅读，更多相关《Citeline&ASGCT：2025年第一季度基因、细胞和 RNA 疗法概况报告（英文版）（55页）.pdf（55页珍藏版）》请在三个皮匠报告上搜索。

1、Gene,Cell,&RNA Therapy Landscape ReportQ1 2025 Quarterly Data ReportAbout the authorsThe American Society of Gene&Cell Therapy(ASGCT)is the primary professional membership organization for scientists,physicians,patient advocates,and other professionals with interest in gene and cell therapy.Our memb

2、ers work in a wide range of settings including universities,hospitals,government agencies,foundations,biotechnology,and pharmaceutical companies.ASGCT advances knowledge,awareness,and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to

3、 benefit patients and society.Citeline,a Norstella company,powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments.These patient-focused solutions a

4、nd services deliver and analyze data used to drive clinical,commercial,and regulatory-related decisions and create real-world opportunities for growth.Our global teams of analysts,journalists,and consultants keep their fingers on the pulse of the pharmaceutical,biomedical,and medtech industries,cove

5、ring it all with expert insights:key diseases,clinical trials,drug R&D and approvals,market forecasts,and more.For more information on one of the worlds most trusted life science partners,visit Citeline.A picture containing drawing,foodDescription automatically generatedTable of contents4Introductio

6、n5Key takeaways from Q1 20256Key highlights in Q1 202516Pipeline overview18Gene therapy pipeline26Non-genetically modified cell therapy pipeline31RNA therapy pipeline37Overview of dealmaking40Start-up funding45Upcoming catalysts47Appendix4/Q1 2025IntroductionWelcome to the first quarterly report of